DexCom, Inc. (NASDAQ:DXCM) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have earned an average recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $98.00.

A number of equities research analysts recently commented on DXCM shares. Royal Bank of Canada decreased their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. JPMorgan Chase & Co. boosted their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a report on Friday, October 25th. Oppenheimer decreased their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Sanford C. Bernstein boosted their price target on DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, Raymond James decreased their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th.

DexCom Trading Down 0.8 %

DexCom stock opened at $79.17 on Wednesday. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a market capitalization of $30.92 billion, a price-to-earnings ratio of 47.41, a price-to-earnings-growth ratio of 2.36 and a beta of 1.12. The stock has a 50-day moving average price of $77.33 and a 200 day moving average price of $78.35.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.30% of the stock is owned by company insiders.

Institutional Trading of DexCom

Large investors have recently made changes to their positions in the company. Versant Capital Management Inc purchased a new stake in shares of DexCom during the fourth quarter worth approximately $25,000. Sachetta LLC grew its holdings in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares in the last quarter. Riverview Trust Co grew its holdings in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in DexCom in the 3rd quarter valued at $57,000. Finally, Covestor Ltd grew its holdings in DexCom by 53.7% in the 3rd quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares in the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.